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A combination of classical site-directed mutagenesis, genetic
code engineering and bioorthogonal reactions delivered a chemically
modiﬁed barstar protein with one or four carbohydrates installed
at speciﬁc residues. These protein conjugates were employed in
multivalent binding studies, which support the use of proteins as
structurally deﬁned scaﬀolds for the presentation of multivalent ligands.
Post-translational protein modiﬁcations play an important role
in the regulation and organization of biological processes of
living organisms and are therefore of common scientiﬁc interest.1
In mammalians, one of the most frequent and complex
modiﬁcation processes is protein glycosylation, which results
in the attachment of oligosaccharides as N- or as O-linked
glycans.2 Glycoproteins play a major role in recognition
events, such as cell–cell interactions, and protein–antigen
recognition.3 Binding events between glycosylated cellular
surfaces and carbohydrate-recognizing proteins4–namely lectins–
often occur in a multivalent or cooperative fashion;5 a mechanism
that is also used by pathogens for infection.6 Interestingly, analogous
monovalent carbohydrates usually only bind to lectins in the
low millimolar range.7 Consequently, investigations focussing
on the understanding of multivalent interactions as well as on
the design of artiﬁcial multivalent binding systems have recently
attracted considerable attention, in particular because carbo-
hydrates and carbohydrate-recognizing proteins are considered
as attractive medicinal targets in cancer research.8 Over the last
few years, numerous groups have explored the multivalency eﬀect
between carbohydrate-presenting scaﬀolds and their receptors.
Commonly utilized scaﬀolds include polymers,9 dextrins,10
nanotubes11 and nanoparticles.12 Although the chemical access
and functionalization of many polymeric systems is well
developed, they often lack information about the exact number
and the structural presentation of the multivalent ligands. For
other scaﬀolds that have addressed these issues, including
fullerenes13 or viral capsids,14 changing the rigidity and ﬂexibility
of the scaﬀold is often limited.
In this communication, we describe a systematic and modular
way for the generation of multivalent binding systems by using
proteins themselves as structured scaﬀolds, which present a
deﬁned number of carbohydrate ligands. This can be achieved
by employing unnatural protein translation for the ribosomal
incorporation of a speciﬁc number of unnatural functional
groups into a protein, which can be chemoselectively conjugated
after expression.15,16 In particular, we used homopropargylglycine
(Hpg, Scheme 1) as a non-canonical amino acid16 in the supple-
mentation incorporation method (SPI), which is based on in vivo
sense codon reassignment. The use of an auxotrophic bacterial
host along with a controlled protein expression allows the residue-
speciﬁc replacement of a particular canonical amino acid by a
non-canonical one.2,15–17 It is important to note that this
modular concept allows the positioning of multivalent ligands
at preselected sites within various protein structures as well as a
straightforward variation of the linker length between the
scaﬀold and the ligands.18
In our model study, we attempted to engineer an artiﬁcially
glycosylated protein for lectin binding studies. We chose the
structurally well-deﬁned cysteine-free ‘‘pseudo-wild-type barstar’’
c-b* from Bacillus amyloliquefaciens as the protein scaﬀold.16,19
c-b* is a 10 kDa protein composed of 90 amino acids with only
one methionine residue.19 The 3D-structure of parent c-b*20
revealed three solvent-exposed positions (K23, E47 and K79)
Scheme 1 The structure of c-b* from Bacillus amyloliquefaciens with
mutations (K23M, E47M and K79M) indicated for c-b*4M.Methionine
was subsequently globally replaced by Hpg during protein expression.
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which were subsequently exchanged to methionine via site-
speciﬁc mutagenesis, giving rise to c-b*4M (Scheme 1). In this
way, four alkyne-containing Hpg amino acids were eﬃciently
introduced to c-b*4M by SPI yielding the congener denoted by
c-b*4M[Hpg], which can be used to conjugate carbohydrates to
barstar to four unnatural residues.16,21 In addition, c-b*1M[Hpg]
was expressed containing a single Hpg at the N-terminus for
comparative lectin binding studies with mono-glycosylated barstar
proteins.
In our studies, we chose the well-established copper-catalyzed
1,3-dipolar azide–alkyne cycloaddition (CuAAC),22 commonly
termed as ‘‘click’’ reaction,23 in particular because of the straight-
forward accessibility of diﬀerent azide-functionalized carbo-
hydrates24 with three linker lengths as well as the high expression
rates of proteins with alkyne-bearing amino acids.15,25
For lectin binding studies of the glycosylated protein scaﬀolds,
peanut agglutinin (PNA) was chosen, for which weak inhibition
with galactose and stronger inhibition with lactose are known.
Consequently, six b-linked azido derivatives of galactose (1–3)
and lactose (4–6) with diﬀerent linker lengths were probed, which
were synthesized from known protocols (see ESIz).9–12,24 The
CuAAC-reaction of c-b*4M[Hpg] with azido-sugars 1–6 was
performed under optimized conditions recently reported by Finn
and coworkers, using tris-(hydroxypropyltriazolylmethyl)amine
(THPTA) as a Cu(I) stabilizing ligand.26 Non-commercially
available THPTA was synthesized in 65% yield by using
Cu(MeCN)4PF6 as catalyst. Strict implementation of the
previously mentioned CuAAC protocol did not lead to fully
functionalized protein, but with an extended reaction time and
lower temperature we managed to get full functionalization of
c-b*4M[Hpg] with all six azido-sugars to yield protein conjugates
b*1–b*6 (Scheme 2A), as veriﬁed by the corresponding gel
shifts in gel electrophoresis andMALDI-ToFMS (see Scheme 2B
and ESIz). Additionally, the single alkyne-containing c-b*1M[Hpg]
showed full conversion with galactose 2 and lactose 5 to mono-
glycosylated b*2[1] and b*5[1] (see ESIz).
After puriﬁcation by dialysis, the inhibitory eﬀect of the
artiﬁcial glycoproteins was probed via a competitive surface
plasmon resonance (SPR) binding assay, where the inhibition
of sugar-functionalized barstar proteins on PNA binding to
the immobilized Thomsen–Friedenreich (TF) antigen was
analyzed. In brief, the TF antigen coupled multivalently to a
polyacrylamide backbone was coated to a Biacore chip surface.
Binding signals of the analytes passed over the chip were
recorded as resonance units (RU). The respective RU for
PNA binding alone was set to 100% and served as positive
control. Potential inhibitory compounds preincubated
with PNA should then demonstrate reduced binding (X% of
control). Measurements were performed with unfunctionalized
c-b*4M[Hpg] as control as well as quadruple functionalized
barstar proteins b*1–b*6 and the mono-functionalized proteins
b*2[1] and b*5[1] (Fig. 1A). Unspeciﬁc inhibition of PNA by
c-b*4M[Hpg] appeared to be very low (approximately 0.2%).
In addition, it was found that the lactose conjugated proteins
b*4, b*5 and b*6 inhibited PNA-binding between 21% and
44%, in which the ethyl-spaced lactose conjugate b*5 showed
the strongest inhibitory eﬀect of all proteins (Fig. 1A). As
expected, the inhibitory eﬀect was signiﬁcantly lower for
galactose conjugates b*1, b*2 and b*3, which can be rationalized
by the previously mentioned lower carbohydrate speciﬁcity of
PNA. Finally, both mono-glycosylated proteins b*2[1] and
b*5[1] showed a signiﬁcantly reduced inhibitory potency,
thereby pointing towards increased binding due to the presentation
of several lactose ligands. Free ligands in contrast showed no
relevant inhibition at all (ESIz).
In the next step, we focussed on the structural analysis of the
lactose scaﬀolds, which showed the strongest inhibitory eﬀect.
Speciﬁcally, we measured the ﬂuorescence of the parent protein
and its conjugates as changes in the emission spectra and
quantum yields represent a speciﬁc ﬁngerprint of the protein
tertiary structure.27 Barstar contains two solvent-exposed Trp
residues (positions 38 and 44) and buried Trp53.19 Trp-residues
not only dominate its absorbance and ﬂuorescence proﬁles but
also play a crucial role in c-b* structural integrity.28 In c-b*
Fig. 1 (A) Relative inhibition of PNA binding measured by SPR in
competition with c-b*4M[Hpg] (denoted as b*) and protein conjugates
b*1–b*6, b*2[1] and b*5[1]. The SPR data for the conjugates were
normalized against the unfunctionalized protein c-b*4M[Hpg];
(B) ﬂuorescence emission spectra of c-b*4M[Hpg] (denoted as b*)
and multivalent lactose glycoprotein conjugates b*4–b*6 and b*5[1]
excited at 280 nm. For experimental details see ESI.z
Scheme 2 (A) Functionalization of c-b*4M[Hpg] with azido-sugars 1–6
by CuAAC. (B) Sodium dodecyl polyacrylamide gel electrophoresis (SDS-
PAGE; 12%) of parent c-b*4M[Met] (left) along with c-b*4M[Hpg]
(second from left) and related protein conjugates b*1–b*6. Expectedly,
migration times of glycoprotein conjugates are shifted when compared
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a network of cooperative interactions exists around Trp53, which
is sandwiched between Phe56 and Phe74.19 These residues play a
central role in maintaining the stability of barstar and all those
features are reﬂected in the ﬂuorescence emission maxima.
As shown in Fig. 1B the ﬂuorescence emission spectrum of
c-b*4M[Hpg] is composed of a typical spectral shoulder
between 330–340 nm (contribution of buried Trp53) and a
peak maximum B350 nm (from solvent-exposed residues
Trp38/Trp44). The proﬁles of its glycoconjugates b*4–b*6
and b*5[1] are essentially identical. Therefore, it can be reasonably
assumed that the structural integrity is not signiﬁcantly
compromised by the conjugation reaction, as no hypsochromic
or bathochromic shift of the ﬂuorescence maximum could be
observed although the shoulder in the b*5[1] spectrum is slightly
more pronounced.
In summary, we have presented a strategy for engineering
an artiﬁcial protein scaﬀold for multivalent binding studies by
conjugation with carbohydrate moieties. We demonstrated
this by introducing one or four galactose and lactose residues
at preselected solvent-exposed sites in a barstar protein by a
combination of unnatural protein translation and bioorthogonal
functionalization. The SPR experiments show that this artiﬁcial
protein scaﬀold acquired the highest capacity to inhibit PNA
binding upon conjugation with four ethylene-glyco spaced
lactose residues as opposed to the mono-glycosylated barstar
protein without any detrimental eﬀect on native tertiary
structure. We anticipate that the high-resolution crystal and
solution structures available for many proteins will oﬀer
almost ideal platforms for decorating those biopolymers with
multivalent ligands, including carbohydrate or even peptide
motifs. This will include proteins with diﬀerent structural
features and various levels of rigidity and will provide a very
promising route for the design of other protein-based multi-
valent systems. We believe that the strategy presented here
provides a solid basis for the further development and design
of molecular systems for multivalent binding studies.
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